that c-Met inhibition alone is not sufficient to exert direct antitumoral or antimigratory effects in neuroendocrine tumor cells. The multi-tyrosine kinase inhibitors cabozantinib and tivantinib show promising antitumoral and antimigratory effects in neuroendocrine tumor cells, which are most probably 'off-target' effects, not mediated by c-Met.
Introduction
Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms mainly originating from the gastroenteropancreatic system and the lung [1] . Molecular targeted therapy of NETs with the mTOR inhibitor everolimus [2, 3] or the multi-tyrosine kinase inhibitor (multi-TKI) sunitinib (VEGFR, PDGFR, KIT) [4] is currently only approved for pancreatic NETs. There is still an unmet need for further medical therapies including novel targeted therapies [5, 6] .
The hepatocyte growth factor (HGF) receptor is encoded by the proto-oncogen c-Met and is a transmembrane tyrosine kinase. The endogenous ligand of c-Met is HGF. The HGF/c-Met axis has been characterized as an important target in cancer therapy [7] [8] [9] [10] as it mediates tumor cell growth, migration and metastasis. Extracellular anti-HGF antibodies, anti-Met antibodies, as well as ATP-competitive and non-ATP competitive MET inhibitors have been developed and are in clinical trial programs [7, 9] . Cabozantinib (XL-184) is an ATP-competitive multi-TKI (with activity against c-Met, VEGFR2, c-KIT, FLT3, RET and TIE2) that has recently been approved by the FDA and EMEA for the treatment of medullary thyroid carcinoma [11, 12] . Cabozantinib is also currently in phase 3 clinical trials for hepatocellular carcinoma (NCT01908426), prostate cancer (NCT01522443) and renal cell carcinoma (NCT01865747). A phase 2 clinical trial with cabozantinib in patients with NET is currently ongoing (NCT01466036). Tivantinib (ARQ-197) is a non-ATP-competitive c-MET kinase inhibitor [7] . Recently, 'off-target' effects of tivantinib have been reported, and antitumoral effects of tivantinib irrespective of c-Met inhibition have been found in vitro [13] [14] [15] [16] . Tivantinib has positive phase 2 trial results [17, 18] , and current phase 3 clinical trials for hepatocellular carcinoma (NCT02029157) and for NSCLC (NCT01377376) are ongoing. INC280 (c-Met) is an ATP-competitive c-MET kinase inhibitor [7] , currently in phase 1/2 clinical trials in various cancer entities.
In preclinical pancreatic neuroendocrine tumor models, various multi-TKIs with combined anti-VEGF and anti-MET efficacy have shown enhanced angiogenesis inhibition, as well as suppression of tumor invasion and metastasis [19] [20] [21] . In the Rip-Tag2 mouse model [19] , the multi-TKIs foretinib (XL880; with activity against cMet, VEGFR2, PDGFR, c-KIT, FLT3, RON and TIE2) and cabozantinib (XL184; with activity against c-Met, VEGFR2, c-KIT, FLT3, RET and TIE2), demonstrated superior inhibition of angiogenesis, reduced tumor invasiveness and reduced metastasis in comparison to the multi-TKI XL999 (with activity against VEGFR2, PDGFR, c-KIT and FLT3). This higher antitumoral efficacy of XL880 and XL184 compared to XL999 might have been caused by their different activities against c-Met with IC50s of 0.4 and 1.3 versus 463 n M [19] . Inhibition of VEGF signaling by an anti-VEGF antibody or by sunitinib in the RIP-Tag2 mouse model reduced tumor growth but caused an increase in phospho-c-Met expression, paralleled by increased lymphatic metastasis. Invasion and metastasis were reduced by the c-Met inhibitors PF-04217903 (with activity against c-Met, ALK) and crizotinib (PF-02341066; with activity against c-Met and ALK) or cabozantinib (XL184; with activity against c-Met, VEGFR2, c-KIT, FLT3, RET and TIE2) [20, 21] . Due to these findings, a role of c-Met as a potential target in neuroendocrine tumors has been suggested [19] [20] [21] . A phase 2 clinical trial with cabozantinib in patients with neuroendocrine tumors is currently ongoing (NCT01466036).
Despite these promising preclinical data for the multi-TKI cabozantinib in neuroendocrine tumors [19] [20] [21] , a direct effect of c-MET inhibition on neuroendocrine tumor cell growth and migration seems not yet proven. The multi-TKI tivantinib has recently been reported in various cancer cells to exert its antitumoral efficacy not related to c-Met inhibition but by other 'off-target' effects [13] [14] [15] [16] . Therefore, we performed a comparative in vitro study using equimolar concentrations of the highly specific c-Met inhibitor INC280 and the multi-TKIs cabozantinib and tivantinib in several human neuroendocrine tumor cell lines. We compared the efficacy of all three compounds on c-Met phosphorylation status, cell viability, cell cycle control, as well as cell migration. In addition, we performed siRNA experiments to knockdown c-MET expression in neuroendocrine tumor cells. Our study demonstrates that c-Met inhibition is not essential for the inhibition of cell growth and cell migration in the investigated neuroendocrine tumor cell models. The observed antiproliferative and antimigratory effects of cabozantinib and tivantinib seem to be mediated by 'off-target' effects other than c-Met.
Materials and Methods

Materials
Dulbecco's modified Eagle medium -Nutrient Mixture F-12, 1: 1 (DMEM/F12) -and penicillin/streptomycin were purchased from Gibco/Invitrogen (Karlsruhe, Germany), trypsin-EDTA (10×) from PAA Laboratories (Cölbe, Germany), phosphate-buffered saline (PBS) and RPMI medium (with L -glutamine, NaCO 3 ) were from Sigma-Aldrich (St. Louis, Mo., USA), and fetal bovine serum (FBS) and amphotericin B were acquired from Biochrom (Berlin, Germany). INC280 was from Novartis (Basel, Switzerland). Cabozantinib and tivantinib were from Selleckchem (Houston, Tex., USA).
Cell Cultures
All human neuroendocrine cell lines were received and cultured as recently described [22] . The human pancreatic neuroendocrine tumor cell line BON1 [23, 24] (kindly provided by Prof. R. Göke, Marburg, Germany) was grown in DMEM/F12 (1: 1) supplemented with 10% FBS, 1% penicillin/streptomycin and 0.4% amphotericin B. The human midgut carcinoid GOT1 cells [25] (kindly provided by Prof. O. Nilsson, Sahlgrenska University Hospital Göteborg, Sweden) and human bronchopulmonary neuroendocrine NCI-H727 tumor cells [26, 27] (purchased from ATCC, Manassas, Va., USA) were cultured in RPMI medium supplement-ed with 10% FBS, 1% penicillin/streptomycin and 0.4% amphotericin B. The cells were mycoplasma free and incubated at 37 ° C in 5% CO 2 /95% air.
Assessment of Cell Viability
BON1 and NCI-H727 cells were counted by an automated cell counter (Countess TM , Invitrogen, Germany), seeded into 96-well plates at densities of 3,000 (BON1) and 4,000 (NCI-H727) cells per well and grown for 24 h in a complete medium containing serum/ antibiotic. The next day, the cells were incubated with various concentrations of INC280, cabozantinib and tivantinib (1 n M to 10 μ M ) in 10% FBS medium (antibiotic free). After 24, 48 and 72 h, the metabolic activity was measured with 'Cell Titer 96 Aqueous One Solution' cell proliferation assay (Promega, Madison, Wis., USA) according to the manufacturer's instructions. The measurement was performed at 492 nm with an ELISA plate reader.
siRNA Transfection
The siRNA transfections were performed as described previously [28] . The siRNA oligonucleotide [ON-TARGETplus SMARTpool, Human MET (4233), Cat. No. 003156-00-0005] and the nontargeting siRNA (ON-TARGETplus Non-targeting Pool, Cat. No. D-001810-10-05) were purchased from Thermo Fisher Scientific (Schwerte, Germany). Cells were transfected in an antibiotic-and FBS-free medium using DharmaFECT 2 (BON1) and Dharmafect 3 (NCI-H727) according to the manufacturer's instructions (Dharmacon, Lafayette, Colo., USA). Twenty-four hours after transfection, FBS was added for a final concentration of 10%.
Cell Cycle Analysis by FACS
Cell cycle distribution was analyzed using propidium iodide staining and flow cytometry (BD Accuri C6 Analysis). Cells were cultured in 6-well plates (4 × 10 5 BON1 cells/well and 5 × 10 5 NCI-H727 cells/well) for 24 h in complete medium. The next day, the medium was replaced with fresh 10% FBS medium and incubated with 10 μ M INC280, cabozantinib and tivantinib. After 24, 48 and 72 h, cells were washed with PBS and treated with 300 μl trypsin at 37 ° C for 4 min. Cells were collected and centrifuged at 2,000 rpm for 5 min. After another wash cycle with PBS, the cells were centrifuged again. The pellets were resuspended in 350 μl propidium iodide. After 2 h, the samples were measured.
Cell Migration Assay
BON1 and NCI-H727 cells were seeded at densities of 120,000/140,000 cells/chamber in culture inserts (Ibidi, Munich, Germany). After 24 h, the inserts were removed, and the cells were treated with 100 n M and 10 μ M of INC280, cabozantinib and tivantinib. Every 24 h, pictures of the gap between the two cell layers were taken [Zeiss, Axiovert 135 TV (microscope) and Zeiss, AxioCam MRm (camera)]. The assay was stopped after 72 h, and pictures were analyzed. 
Protein Extraction and Western Blotting
Statistical Analysis
For proliferation assays, comparisons were evaluated using two-tailed Student's t test. Results are expressed as mean ± SD of three or four independently performed experiments. Statistical significance was set at p < 0.05.
Results
Human Neuroendocrine Tumor Cells Express Functional c-Met and Its Endogenous Ligand HGF
Western blot analysis demonstrated the expression of c-Met in human pancreatic neuroendocrine BON1, bronchopulmonary NCI-H727 and midgut GOT1 tumor cells, respectively ( fig. 1 a) . Expression of the endogenous c-Met ligand HGF was found in BON1 and H727 tumor cells, but not in GOT1 cells ( fig. 1 b) . Incubation of BON1, H727 and GOT1 cells with recombinant human HGF (rhHGF) at a concentration of 1.25 n M for 10 min caused a significant induction of phospho-c-Met Y1234/5, while preincubation with the c-Met-inhibitor INC280 at a concentration of 100 n M for 2 h completely abolished the baseline and HGF-stimulated phospho-c-Met Y1234/5 ( fig. 1 a) . In addition, rhHGF stimulated phosphorylation of Akt and ERK1/2, while preincubation with the c-Metinhibitor INC280 at a concentration of 100 n M for 2 h prevented any stimulation ( fig. 1 a) .
Thus, these data demonstrate the expression of a functional c-Met receptor on all three human neuroendocrine tumor cell lines investigated. However, the expression of the endogenous c-Met ligand HGF and expression of activated c-Met (phospho-c-Met Y1234/5) in untreated cells were only found in BON1 and H727 cells, while it could not be detected in GOT1 cells.
Cabozantinib and Tivantinib Inhibit Cell Viability of Neuroendocrine Tumor Cells, while the Specific c-Met Inhibitor INC280 Has No Effect
Human pancreatic neuroendocrine BON1, bronchopulmonary NCI-H727 and midgut GOT1 tumor cells were incubated with INC280, cabozantinib and tivantinib at a concentration range of 1 n M to 10 μ M , for 24 h ( fig. 2 a) , 48 h ( fig. 2 b) and 72 h ( fig. 2 c) , respectively. Cabozantinib and tivantinib at lower concentrations of 1 and 100 n M demonstrated no constant significant effects on cell viability of the three tumor cell lines. However, cabozantinib 10 μ M caused a significant decrease in cell viability in BON1, H727 and GOT1 cells, each at 24, 48 and 72 h, respectively ( fig. 2 ) . At 72 h, cabozantinib 10 μ M caused a decrease in cell viability in BON1 cells to 51.1 ± 2.3% (p < 0.001), H727 cells to 59.3 ± 2.1% (p < 0.001) and GOT1 cells to 30.5 ± 9.3% (p < 0.01), respectively. Also tivantinib 10 μ M caused a significant decrease in cell viability in BON1 and H727 cells at 24, 48 and 72 h, respectively ( fig. 2 ), but had no effect on cell viability of GOT1 cells ( fig. 2 ) . At 72 h, tivantinib 10 μ M caused a decrease in cell viability in BON1 cells to 28.1 ± 5.2% (p < 0.001) and in H727 cells to 65.9 ± 7.4% (p < 0.01). In contrast, no significant effect of tivantinib 10 μ M was observed on cell viability of GOT1 cells [98.8 ± 13.9% (n. Thus, these data demonstrate that inhibition of c-Met expression does not affect or only minimally affects cell viability of neuroendocrine tumor cells.
Inhibition of c-Met Expression by c-Met siRNA Does Not Inhibit Cell Viability of Neuroendocrine Tumor Cells
Differential Effects of INC280, Cabozantinib and Tivantinib on c-Met Activity and EGFR, Akt and MAPK Signaling
Human pancreatic BON1 and bronchopulmonary NCI-H727 cells were incubated with INC280, cabozantinib and tivantinib, respectively, in concentrations of 1, 100 and 10,000 n M for 24 h, followed by protein extraction and Western blot analysis ( fig. 4 a) . Expression of activated phospho-c-Met Y1234/5 was already partially inhibited by INC280 and cabozantinib at the lowest concentration of 1 n M , while concentrations of 100 and 10,000 n M completely abolished phospho-c-Met Y1234/5 expression, respectively ( fig. 4 a) . In contrast, tivantinib demonstrated a partial inhibition of phospho-c-Met Y1234/5 expression in BON1 cells only at the highest concentration of 10,000 n M ( fig. 4 a) . Thus, these data demonstrate that the c-Met-inhibitor efficacy of INC280 and cabozantinib in neuroendocrine tumor cells is in a similar low nanomolar range, while tivantinib, even at the highest concentration tested, caused only a partial inhibition of activated phospho-c-Met Y1234/5 expression ( fig. 4 a) . As Akt/mTOR signaling and MAPK signaling is essentially involved in neuroendocrine tumor cell proliferation [28] [29] [30] , an analysis of various markers of Akt/mTOR signaling and MAPK signaling was performed ( fig. 4 b, c) . Human pancreatic BON1 and bronchopulmonary NCI-H727 cells were incubated with INC280 (10,000 n M ), cabozantinib (10,000 n M ) and tivantinib (10,000 n M ) for 2, 24, 48 and 72 h, respectively, followed by protein extraction and Western blot analysis ( fig. 4 b, c) . Cabozantinib and tivantinib caused late-onset effects at 48 and 72 h with a decrease in phospho-EGFR in BON1 and NCI-H727 cells ( fig. 4 b, c) . Cabozantinib also demonstrated an early negative effect on phospho-IGF-1R at 2 h in BON1 and NCI-H727 cells ( fig. 4 b, fig. 4 b) and by cabozantinib and tivantinib at 24 h in H727 cells ( fig. 4 c) . In contrast, none of the above described effects were observed in a similar manner with INC280 ( fig. 4 b, c) .
Cabozantinib and Tivantinib Cause a G2 Arrest of Neuroendocrine Tumor Cells, while the Specific c-Met Inhibitor INC280 Has No Effect
Human pancreatic neuroendocrine BON1 ( fig. 5 a, b) and bronchopulmonary NCI-H727 ( fig. 5 c, d ) cells were incubated with equimolar concentrations (10,000 n M ) of INC280, cabozantinib and tivantinib for 24 h, followed by FACS analysis. In BON1 cells, cabozantinib and tivantinib caused a significant accumulation in G2 phase with 54.9 ± 13.9% (p < 0.05) and 75.6 ± 7.9% (p < 0.01) versus 17.5 ± 3.2% G2 phase in the control group ( fig. 5 b) . In H727 cells, cabozantinib and tivantinib caused a significant accumulation in G2 phase with 31.9 ± 4.4% (n.s., p = 0.2) and 53.7 ± 4.7% (p < 0.05) versus 26.6 ± 6.4% G2 phase in the control group ( fig. 5 d) . In contrast, INC280 did not exert a significant effect on the percentage of cells in the G2 phase neither in BON1 cells with 17.0 ± 5.3% (n.s.) versus 17.5 ± 3.2% G2 phase in the control group 
Differential Effects of INC280, Cabozantinib and Tivantinib on c-Met Activity and Various Parameters of Cell Cycle Regulation and Apoptosis
Human pancreatic BON1 and bronchopulmonary NCI-H727 cells were incubated with INC280 (10,000 n M ), cabozantinib (10,000 n M ) and tivantinib (10,000 n M ) for 2, 24, 48 and 72 h, respectively, followed by protein extraction and Western blot analysis ( fig. 6 a, b) .
Cabozantinib and tivantinib demonstrated late-onset effects at 72 h with inhibition of the expression of cyclin D1 and proliferation marker PCNA in BON1 cells ( fig. 6 a) and H727 cells ( fig. 6 b) . Tivantinib upregulated cyclin B1 expression at 24 h in BON1 cells ( fig. 6 a) and H727 cells ( fig. 6 b) . While these findings indicate that cabozantinib and tivantinib affect cell cycle regulation, cabozantinib or tivantinib had no effect on cleavage of the apoptosis marker PARP ( fig. 6 a, b) .
Cabozantinib and tivantinib cause a G2 arrest in BON1 and H727 cells ( fig. 5 ) . Therefore, we also investigated protein expression of the G2 checkpoint regulator Chk1.
The effects of cabozantinib or tivantinib on pChk1S345/ Chk1 expression were different in BON1 and H727 cells ( fig. 6 a, b) , indicating a cell type-specific regulation.
Cabozantinib and Tivantinib Inhibit Cell Migration of Neuroendocrine Tumor Cells, while the Specific c-Met Inhibitor INC280 Has No Effect
Human pancreatic neuroendocrine BON1 ( fig. 7 a, b) and bronchopulmonary NCI-H727 ( fig. 7 c, d ) cells were incubated with INC280, cabozantinib and tivantinib, respectively, at a concentration of 100 n M and 10 μ M for 72 h. The gap width at 0 and 72 h, respectively, for each treatment group was analyzed ( fig. 7 b, d) . In BON1 cells, cabozantinib and tivantinib at the highest concentration of 10,000 n M inhibited cell migration into the gap and restored the gap width with 84.7 ± 3.4% (p < 0.05) and 82.9 ± 17.9% (n.s., p = 0.1), respectively ( fig. 7 b) . In contrast, INC280 had no significant inhibitory effect on cell migration into the gap and did not restore the gap width in comparison to control with 9.3 ± 11.3% (n.s., p = 0.1) versus 29.2 ± 19.2% ( fig. 7 b) . In H727 cells, cabozantinib and tivantinib inhibited cell migration into the gap and restored the gap width with 102.5 ± 20.6% (p < 0.05) and 66.1 ± 2.2% (p < 0.05), respectively ( fig. 7 d) . In contrast, INC280 had no significant inhibitory effect on cell migration into the gap and did not restore the gap width in comparison to control with 33.7 ± 16.8% (n.s., p = 0.5) versus 38.9 ± 7.0% ( fig. 7 d) .
Thus, these data demonstrate that cabozantinib and tivantinib at a concentration of 10 μ M inhibit cell migration in human neuroendocrine tumor cell lines, while INC280 does not. The antimigratory effects of INC280, cabozantinib and tivantinib ( fig. 7 ) are not correlated and not congruent with their efficacy as a c-Met inhibitor ( fig. 4 ) , as demonstrated before.
Next, we evaluated whether the antimigratory effects of cabozantinib and tivantinib are mediated by epithelial mesenchymal transition (EMT) markers. However, no effects were detected in Western blot analysis of a panel of appropriate EMT markers ( fig. 8 ).
Discussion
The HGF/HGF receptor c-Met axis has been defined as a potential target in cancer therapy of various tumor entities [7] [8] [9] [10] . In this study, we aimed to investigate whether single c-Met inhibition is sufficient to inhibit neuroendocrine tumor cell growth and migration in vitro, and to further characterize the role of the HGF/c-Met axis in neuroendocrine tumors. The effects of the multi- Expression of c-Met has been reported as a putative target in neuroendocrine tumors [31, 32] . In 39 pancreatic neuroendocrine neoplasms, protein expression analysis revealed c-Met overexpression in 17% (4/24) of nonmetastasized NET, 33% (5/15) of metastasized NET, 57% (4/7) of lymph node metastases and 56% (5/9) of liver metastases, respectively [33] . In human pancreatic neuroendocrine BON1 cells, microarray analysis using a small array of 2,503 genes revealed 101 HGF-responsive genes, including genes with a putative function in oncogenesis, cell proliferation, apoptosis or cell adhesion/motility [34] . In 10 gastrinomas, protein expression of HGF receptor c-Met was detectable in 90%, while competitive PCR in 38 gastrinomas revealed c-Met overexpression in 14% compared to normal pancreas [35] . Overexpression of c-Met was a negative prognostic indicator in gastrinomas [35] . In 17 ileal NETs and 28 nonileal NETs, high staining of c-Met immunoreactivity was found in 100% of ileal NETs and 32% of nonileal NETs [36] . The human midgut carcinoid cell line CNDT2 expresses c-Met [37] . In bronchopulmonary neuroendocrine neoplasms, strong c-Met expression was observed in 66% (25/38) of typical carcinoids, 67% (4/6) of atypical carcinoids, 50% (17/34) of SCLC and 55% (6/11) of LCNEC [38] . A strong expression of activated phospho-c-Met was observed in [38] . C-Met mutations have been reported to be relatively rare in bronchopulmonary neoplasias with 6.5% in 46 SCLC and 8.3% in 36 NETs [39] . These mutations were not functionally relevant in regard of c-Met phosphorylation status [39] . Serum levels of HGF were significantly higher in patients with bronchopulmonary carcinoid tumors than in healthy controls [40] . er efficacy compared to cabozantinib and with an approximately 100-to 1,000-fold higher efficacy compared to tivantinib. This different potency in inhibition of c-Met phosphorylation was also found in our experiments comparing INC280, cabozantinib and tivantinib ( fig. 4 a) . Similar to our data, also in epithelioid sarcoma cell lines has the highly selective c-Met inhibitor INC280 been reported to inhibit phospho-c-Met at concentrations of 1 n M [44] . Although in our study equimolar concentrations (10 μ M ) of cabozantinib and tivantinib potently inhibited cell viability ( fig. 2 ) and cell migration ( fig. 7 ) , the highly specific c-Met inhibitor INC280 had no effect on cell viability ( fig. 2 ) or cell migration ( fig. 7 ) . Similarly, equimolar concentrations (10 μ M ) of cabozantinib and tivantinib caused a potent G2 arrest in neuroendocrine tumor cells, while INC 280 had no effect ( fig. 5 ). Knockdown experiments with c-Met siRNA also demonstrated no effect or only minor effects on neuroendocrine tumor cell viability ( fig. 3 ). Our in vitro data suggest that c-Met inhibition alone is not sufficient to exert direct antitumoral or antimigratory effects in neuroendocrine tumor cells in vitro. In contrast, the multi-TKIs cabozantinib and tivantinib show promising antitumoral and antimigratory effects in neuroendocrine tumor cells, which are most probably 'off-target' effects, not mediated by c-Met.
In the Rip-Tag2 mouse model of pancreatic neuroendocrine tumors, the multi-TKI cabozantinib (with activity against c-Met, VEGFR2, c-KIT, FLT3, RET and TIE2) has been demonstrated to be superior in comparison to compounds with anti-VEGF activity only in inhibition of tumor angiogenesis, tumor invasiveness and metastasis [19, 21] . Further studies in the Rip-Tag2 mouse model with an anti-VEGF antibody or sunitinib in combination with the c-Met inhibitor PF-04217903 [19, 21] also showed additive antitumoral effects. The antitumoral effects of cabozantinib in the Rip-Tag2 mouse model have been discussed to be due to simultaneous inhibition of VEGF and c-Met signaling by cabozantinib [19, 21] . However, due to the multi-TKI function of cabozantinib (with known ac- [19, 21] . Our in vitro data suggest that c-Met inhibition alone is not sufficient to exert direct antitumoral or antimigratory effects in unstimulated neuroendocrine tumor cells.
Nevertheless, in neuroendocrine tumor cells with compensatory upregulation of phospho-c-Met expression, inhibition of c-Met might be a specific target for antitumoral and antimigratory effects [21] . In human pancreatic cancer cells in vitro, INC280 inhibited HGFinduced cell growth and migration, while no effect of INC280 was observed on constitutive cell growth and migration in cells that were not stimulated by HGF [45] . In hepatocellular tumor cell models, cabozantinib caused a G1 arrest in the phospho-c-Met-overexpressing tumor cell lines MHCC97L and MHCC97H (cabozantinib IC 50 values for inhibition of cell growth 9-13 n M ), while in the non-phospho-c-Met-expressing tumor cell lines SK-HEP1 and HepG2 (cabozantinib IC 50 values for inhibition of cell growth 4,300-5,000 n M ), a G2 arrest was observed [46] . These data suggest different c-Met-dependent and c-Met-independent mechanisms of cabozantinib on cell cycle in tumor cells [46] .
In accordance with our results in neuroendocrine tumor cells, tivantinib has recently been reported to exert antitumoral effects in various tumor entities, which are an offtarget of c-Met inhibition [13] [14] [15] [16] . In thyroid cancer cells, siRNA-mediated downregulation of c-Met did not induce cell cycle arrest or apoptosis [14] . There was no correlation between the c-Met inhibitory potency of crizotinib and tivantinib and their respective antitumoral efficacy in thyroid tumor cells [14] . In various tumor cell entities, tivantinib inhibited c-Met addicted and nonaddicted tumor cells in a similar fashion [15, 16] , suggesting a c-Met-independent mechanism of action. Tivantinib has been suggested to cause antitumoral effects by alternative mechanisms as microtubule disruption [15, 16, 43] or inhibition of GSK3α and GSK3β [44] . Tivantinib caused a significant G2 arrest in various tumor cells [13] [14] [15] [16] , while the c-Met inhibitors crizotinib and PHA-665752 caused a G1 arrest [15] .
In our neuroendocrine tumor cell model in vitro, cabozantinib and tivantinib demonstrated late-onset 72-hour effects with inhibition of the expression of pEGFR ( fig. 4 ), pAktS473 ( fig. 4 ), p4EBP1S65 ( fig. 4 ) and cyclin D1 ( fig. 6 ). In addition, cabozantinib constantly induced GSK3 phosphorylation at pGSK3 S21/9 in both cell lines at 72 h ( fig. 4 ). Cabozantinib and tivantinib modestly inhibited the proliferation marker PCNA at 72 h ( fig. 6 ) and caused a potent G2 cycle arrest ( fig. 5 ) in BON1 and H727 cells. These data indicate that cabozantinib and tivantinib decrease tumor cell viability, most probably due to inhibition of cell proliferation mediated by inhibition of pAkt and its downstream signals and by upregulation of pGSK3. In contrast, no PARP cleavage as a marker of apoptosis was detected ( fig. 6 ). Accordingly, c-Met inhibitors have been reported to inhibit downstream Akt and MAPK signaling cascades in various tumors [7, 9, 46] . Inhibition of Akt/mTOR signaling is a proven, important target in neuroendocrine tumor cells [28, 30] . The phosphorylation of GSK3 causes its inactivation [47] .
Cabozantinib and tivantinib cause a G2 cycle arrest in BON1 and H727 cells ( fig. 5 ). Accordingly to our data, a G2 arrest has also been reported in other in vitro cancer models with cabozantinib [42] and tivantinib [13] [14] [15] [16] . Tivantinib has been reported to cause G2 cell cycle arrest in [15] . Phosphorylation and activation of the cell cycle G2 checkpoint regulator Chk1 is known to cause subsequent phosphorylation and inactivation of the phosphatase CDC25. Inactivation of CDC25 phosphatase prevents dephosphorylation and activation of CDK1 in the cyclin B/CDK1 complex and finally inhibits progression to mitosis [48] . On the other hand, Chk1 inhibitors have been suggested as a potential target to sensitize cancer cells [48] . The effects of cabozantinib or tivantinib on the cell cycle G2 checkpoint regulator Chk1 were different in BON1 and H727 cells ( fig. 6 a, b) , indicating a cell type-specific regulation. Further studies are necessary to evaluate the mechanisms by which cabozantinib and tivantinib cause G2 cell cycle arrest in our neuroendocrine tumor cell model.
Our study clearly demonstrates that single c-Met inhibition with the highly specific c-Met inhibitor INC280 is not sufficient to exert direct antiproliferative effects or inhibition of tumor cell migration in neuroendocrine tumor cells in vitro under constitutive conditions. Neuroendocrine tumor cells without pretreatment were not dependent on c-Met signaling for growth, survival or migration. Thus, based on our in vitro data, it seems not to be a promising strategy to target neuroendocrine tumors in monotherapy with highly specific c-Met inhibitors. However, the limitations of an in vitro model of NET to study their tumor biology have to be stated as follows: (a) there is only a limited number of human cell lines available [24, 27] , and (b) the cell proliferation rates of many rapidly growing cell culture models do not match the slow proliferation index Ki-67 of typical G1 and G2 NET.
In contrast, we observed potent antiproliferative effects and inhibition of tumor cell migration by the multiTKIs cabozantinib and tivantinib in neuroendocrine tumor cells in vitro. Our data suggest these in vitro effects of cabozantinib (multi-TKI with known activity against c-Met, VEGFR2, c-KIT, FLT3, RET and TIE2) and tivantinib (c-Met inhibitor with additional 'off-target' effects [13] [14] [15] [16] ) to be most likely mediated by 'off-target' effects besides c-Met. These findings may have implications for the rationale of future selection of multi-TKIs for neuroendocrine tumor treatment and for the evaluation of phospho-c-Met expression as a potential biomarker for response prediction in neuroendocrine tumors.
Single c-Met inhibition seems insufficient to exert direct antitumoral effects in unstimulated neuroendocrine tumor cells. Nevertheless, a synergistic action of c-Met inhibition during combination therapy targeting several signaling cascades cannot be excluded by our data. As stated above, in cancers with compensatory upregulation of phospho-cMet expression, inhibition of c-Met seems to exert antitumoral and antimigratory effects [21, 49] . In other various tumor entities, resistance against EGFR inhibition or resistance against anti-VEGF therapy has been demonstrated to be mediated by compensatory upregulation of phosphorylated c-Met as an alternative signaling pathway. Inhibition of c-Met has been discussed as a potential target in combination therapies in order to overcome a c-Met-induced escape from EGFR inhibition [50] [51] [52] [53] [54] [55] [56] or escape from anti-VEGF therapy [31, [57] [58] [59] [60] , as has been demonstrated in various tumor entities. These mechanisms have also been discussed for neuroendocrine tumors [19-21, 31, 61] . Further preclinical in vivo studies in xenograft models of human NET treated with appropriate combination therapies including the highly specific c-Met inhibitor INC280 should be performed to address this issue. is a highly selective c-MET inhibitor, and its further evaluation in c-Met-dependent tumor entities, as cancers with constitutive or compensatory upregulation of phospho-c-Met expression, is warranted.
Our in vitro data demonstrate that cabozantinib and tivantinib with potent antiproliferative effects in neuroendocrine tumors are most probably mediated by 'offtarget' effects not mediated by c-MET inhibition. Further investigation of these compounds as antitumoral agents in neuroendocrine tumors is warranted. Currently, a clinical phase 2 study of cabozantinib in neuroendocrine tumors (NCT01466036) is recruiting patients.
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